Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Idiopathic membranous glomerulonephritis (IMG) is a primary glomerular disease characterized by proteinuria, usually in the nephrotic range, with preserved renal function.
Estimated prevalence: Unknown (Unknown prevalence).
8 clinical trials registered, 5 recruiting. Interventions under study include drug therapy and other interventions. Pipeline includes 2 PHASE4, 2 PHASE3, 2 PHASE2. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT04745728](https://clinicaltrials.gov/study/NCT04745728) |
Data assembled from 5 of 12 sources · Last updated Sep 19, 2026, 3:32 AM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Different Immunosuppressive Treatment in iMN
PHASE3 |
Peking Union Medical College Hospital |
RECRUITING |
[NCT07423572](https://clinicaltrials.gov/study/NCT07423572) | Clinical Study of Anti-CD19/BCMA Universal Chimeric Antigen Receptor T Cells (UCAR-T) in the Treatment of Refractory Idiopathic Membranous Nephropathy (IMN) | EARLY_PHASE1 | The First Affiliated Hospital of Zhejiang Chinese Medical University | NOT_YET_RECRUITING |
[NCT04456816](https://clinicaltrials.gov/study/NCT04456816) | A Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Treatment With AP1189 in Patients With iMN and Severe Proteinuria | PHASE2 | SynAct Pharma Aps | UNKNOWN |
[NCT00977977](https://clinicaltrials.gov/study/NCT00977977) | Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy | PHASE2 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | RECRUITING |
[NCT05839314](https://clinicaltrials.gov/study/NCT05839314) | Effect of Huaier Granule on the Treatment of Idiopathic Membranous Nephropathy | PHASE4 | Chinese PLA General Hospital | RECRUITING |
3 publications have been identified in PubMed for idiopathic membranous glomerulonephritis. Research spans Review / Meta-Analysis (33%), Clinical Trial Publication (33%), and Basic Science / Preclinical (33%).
Yin T (2026). [PMID: 42051255](https://pubmed.ncbi.nlm.nih.gov/42051255/). *Front Pharmacol*. [Review / Meta-Analysis]
Hengel FE (2024). [PMID: 38804512](https://pubmed.ncbi.nlm.nih.gov/38804512/). *The New England journal of medicine*. [Clinical Trial Publication]
Montenegro F (2024). [PMID: 39273032](https://pubmed.ncbi.nlm.nih.gov/39273032/). *Cells*. [Basic Science / Preclinical]